Eggshell Membrane

Eggshell Membrane

The implantable pumps market is expected to register a CAGR of approx. 5.7% over the period of 2023-2030. Implantable pumps are medical devices designed to deliver a controlled amount of medication or fluids directly into the body. These pumps are typically implanted under the skin and are used for various therapeutic purposes, such as pain management, chemotherapy, and insulin delivery for diabetes. The growing demand for implantable pumps can be attributed to the increasing incidence of chronic diseases such as cardiovascular diseases, cancer, etc. are the key factors which boost the adoption around the globe. For instance, according to the CDC, One person dies every 33 seconds in the United States from cardiovascular disease. About 695,000 people in the United States died from heart disease in 2021—that’s 1 in every 5 deaths. Furthermore, ongoing advancements in technology, including miniaturization, improved battery life, and enhanced programmability, can make these devices more efficient and user-friendly, expanding their applications, have been a key driver. Moreover, implantable pumps plays a crucial role in oncology for the detection and evaluation of tumours. The rising incidence of cancer cases worldwide has driven the demand for implantable pumps procedures. In 2021, cancer remained a significant healthcare concern.

• Based on the product type, the market has been categorized into patient-controlled analgesia (pca) pump, enteral pump, insulin pump, elastomeric pump, and syringe pump. Among them, the insulin pump segment is expected to grow at a higher CAGR in the market. PCA pumps are designed to provide more efficient pain management by allowing patients to receive smaller, more frequent doses of pain medication. This can lead to better pain control and improved patient outcomes.
• Based on the application, the market has been categorized into oncology, pediatrics/neonatology, gastroenterology, hematology, and diabetes. Among them, the oncology segment is expected to grow at a higher CAGR in the market. Implantable pumps are often used for pain management in cancer patients. These devices can deliver controlled and continuous doses of pain medication directly to the affected area, providing more targeted relief. Furthermore, some implantable pumps are designed for intrathecal drug delivery, which can be crucial in delivering chemotherapy drugs directly to the cerebrospinal fluid around the spinal cord. This targeted approach can be more effective in treating certain types of cancers.
• Based on the end-user, the market has been categorized into hospitals and clinics, ambulatory surgical centres, home healthcare. Among them, the hospitals and clinics category is to witness higher adoption of implantable pumps during the forecast period. The hospitals segment is a key driver of the implantable pumps market due Implantable pumps are often used in the treatment of chronic diseases such as chronic pain, diabetes, and cancer. As the prevalence of these conditions continues to rise, there is an increasing demand for implantable pump devices.
• For a better understanding of the market adoption of the implantable pumps industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America implantable pumps market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of implantable pumps among healthcare professionals and the general population, development of advanced techniques and the rise in treatment option. For instance, in 2020, according to American Cancer Society, Cancer is the second most common cause of death in the US, exceeded only by heart disease. around 609,360 deaths from cancer are expected in the US in 2022, which is about 1,670 deaths per day.
• Some of the major players operating in the market include Becton, Dickinson and Company, B.Braun Melsungen AG, Medtronic, AngioDynamics, Novo Nordisk A/S., Johnson and Johnson Services, Inc, Pfizer Inc, Baxter, Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc.